Tokano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, Yagita H, Takasaki Y, Okumura K, Hashimoto H
Department of Rheumatology and Internal Medicine, Juntendo University, School of Medicine, Tokyo, Japan.
J Clin Immunol. 1996 Sep;16(5):261-5. doi: 10.1007/BF01541390.
The serum level of soluble Fas (sFas) molecules in 35 patients with SLE was determined by enzyme-linked immunosorbent assay (ELISA) and its relation to other lymphocyte activation markers and clinical parameters was examined. The level of sFas increased significantly compared to that in normal subjects, consistent with previous reports. There was a significant correlation between the level of sFas and that of sCD4, suggesting some relation between sFas and activation of CD4+ T cell. Patients with lymphopenia tended to have low levels of sFas, making it possible to hypothesize that sFas protects against apoptosis. Although the change in the level of sFas protects steroid therapy was variable, some relation to the differential activation of T cell subsets was suggested.
采用酶联免疫吸附测定（ELISA）法测定了35例系统性红斑狼疮（SLE）患者血清中可溶性Fas（sFas）分子水平，并检测了其与其他淋巴细胞活化标志物及临床参数的关系。与正常受试者相比，sFas水平显著升高，与先前报道一致。sFas水平与sCD4水平之间存在显著相关性，提示sFas与CD4+T细胞活化之间存在某种关系。淋巴细胞减少的患者sFas水平往往较低，因此可以推测sFas可防止细胞凋亡。虽然sFas水平在类固醇治疗后的变化各不相同，但提示其与T细胞亚群的差异活化存在一定关系。
